Welcome to our dedicated page for Telomir Pharms SEC filings (Ticker: TELO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures, offering a structured view of how this preclinical-stage biotechnology company reports its progress and corporate events. Telomir’s filings show that it is a Florida corporation with common stock listed on The Nasdaq Stock Market LLC under the symbol TELO, and they document its focus on developing Telomir-1, a small-molecule therapy targeting epigenetic and metabolic mechanisms in cancer and age-related disease.
For Telomir, Form 8‑K current reports are especially informative. Recent 8‑Ks include Item 8.01 disclosures of new preclinical data, such as Telomir-1’s effects on PSA levels in prostate cancer cells, tumor growth and metastasis in triple-negative breast cancer models, cytotoxicity in leukemia cells, and reductions in intracellular iron compared with the iron chelator Deferoxamine. Another 8‑K details completion of GLP toxicology and safety pharmacology studies in rat and dog models, noting that Telomir-1 was generally well tolerated with no treatment-related adverse or dose-limiting toxicities observed.
Filings also cover corporate and governance matters. Examples include an 8‑K describing a director resignation, compensation committee actions regarding the chief executive officer’s incentives, and a Nasdaq notice related to the timing of the company’s annual shareholder meeting under Listing Rule 5620(a). An additional 8‑K outlines a binding Letter of Intent to acquire TELI Pharmaceuticals, Inc., intended to consolidate worldwide intellectual property and development rights to Telomir-1 within a single public company structure.
On Stock Titan, these filings are supplemented by AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand the implications of GLP safety data, oncology study updates, compensation decisions, and Nasdaq communications. Users can review real-time updates from EDGAR, examine narrative descriptions of Telomir-1’s preclinical profile, and track how Telomir reports its IND-enabling activities and strategic transactions over time.
Telomir Pharmaceuticals, Inc. disclosed that Nasdaq has notified the company it is not in compliance with Nasdaq Listing Rule 5620(a), which requires listed companies to hold an annual shareholder meeting within twelve months after the end of their fiscal year. The company had planned to hold its annual meeting on December 30, 2025, but its preliminary proxy statement remains under SEC review.
Nasdaq’s notice does not immediately affect the listing or trading of Telomir’s common stock on the Nasdaq Capital Market. Telomir has until February 23, 2026 to submit a plan to regain compliance, and Nasdaq may grant additional time if it accepts that plan. After the SEC review is completed, Telomir expects to promptly hold its annual meeting and regain compliance and states it intends to take all necessary steps within the applicable cure period.
Telomir Pharmaceuticals reported new incentive arrangements for its Chief Executive Officer, Erez Aminov. Following a review of 2025 performance, the Compensation Committee approved a 2025 short‑term incentive payout of $400,000, based on operational execution, financing activities, and program advancement.
The Board also granted a $150,000 milestone award that will be paid only if the FDA accepts the Company’s future IND submission for its Telomir‑1 program; no IND has been submitted yet. In connection with the potential acquisition of TELI Pharmaceuticals, Inc., the Board approved a transaction advisory award equal to 3% of the total TELI transaction value, payable in cash, equity, or a mix, at the CEO’s election, with any equity vesting immediately at closing. In addition, the CEO’s base salary was set at $500,000 effective January 1, 2026, based on external benchmarking and advice from an independent compensation consultant.
Telomir Pharmaceuticals, Inc. reported favorable results from a full package of Good Laboratory Practice toxicology and safety pharmacology studies for its lead candidate, Telomir-1 (Zn-Telomir). The completed cardiovascular, respiratory, phototoxicity, and repeat-dose studies in in vitro systems and in rat and dog models showed Telomir-1 was generally well tolerated, with no treatment-related adverse or dose-limiting toxicities and only limited, reversible, non-adverse findings. In non-rodent dog studies, no test-article-related changes in blood pressure, heart rate, ECG parameters, or body temperature were seen after oral dosing, and oral studies showed consistent systemic exposure.
These results support advancement into first-in-human clinical trials, with no findings identified that would prevent clinical entry, subject to regulatory pathways. The company plans to submit an Investigational New Drug application in the first quarter of 2026 and aims to start first-in-human clinical studies in the first half of 2026 while continuing preclinical work in oncology and age-related diseases and preparing manuscripts and scientific conference submissions.
Telomir Pharmaceuticals, Inc. (TELO) announced new preclinical data on its investigational candidate Telomir-1 in prostate cancer models. In an in vitro study using androgen-responsive human prostate cancer LNCaP cells, Telomir-1 reduced prostate-specific antigen (PSA) levels in a dose-related manner. PSA is an FDA-recognized biomarker where higher levels generally indicate more active tumor behavior.
The company also highlighted prior mouse data in a PC3 xenograft model of aggressive, non-androgen-related prostate cancer, where Telomir-1 reduced tumor volume as a single agent, and in combination with paclitaxel achieved full tumor volume reduction without treatment-related mortality, while paclitaxel alone caused high mortality. Telomir continues preclinical development of Telomir-1 across oncology, aging biology, autism-related pathways and other age-associated conditions, and is advancing IND-enabling work toward a planned IND submission.
Telomir Pharmaceuticals, Inc. reported that Board member Craig Eagle resigned from the Board of Directors, effective November 14, 2025. The company states that his resignation was not due to any disagreement with Telomir, its management, or any other Board member. The Board expressed appreciation for his service. A copy of Mr. Eagle’s resignation letter is included as Exhibit 17.1 to this report.
Telomir Pharmaceuticals (TELO) is asking stockholders to approve a merger with private TELI Pharmaceuticals at a virtual annual meeting on December 30, 2025. The key item is authorization to issue TELO common stock and other securities in the merger equal to more than 20% of TELO shares outstanding, along with electing four directors, ratifying the auditor, amending the 2023 Omnibus Incentive Plan and bylaws, approving director option grants, and allowing adjournments.
Under the Merger Agreement, TELI stockholders will exchange their TELI shares for TELO common stock based on an exchange ratio derived from valuations of about $101.1 million for TELO and $126.8 million for TELI. Immediately after closing, pre‑merger TELO and TELI holders are expected each to own approximately 50% of TELO on a non‑diluted basis, shifting to about 59% for TELI holders on a fully diluted basis when 14,250,000 Telomir‑linked warrants at $2.00 per share are included.
TELO holds U.S. rights to the pre‑clinical drug candidate Telomir‑1, while TELI licenses major international rights, so the merger is intended to consolidate global Telomir‑1 development and commercialization within a single Nasdaq‑listed company. The board unanimously recommends voting in favor of all proposals but highlights extensive risk factors, including TELI’s lack of revenue, significant funding needs for combined operations, clinical and regulatory uncertainty, competitive pressures, and potential dilution to existing TELO stockholders.
Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) reported new preclinical results showing its investigational small molecule Telomir-1 killed aggressive human leukemia (HL60) cells in vitro. The compound produced a clear, dose-dependent reduction in leukemia cell viability in this widely used model of acute myeloid leukemia.
The company links these findings to earlier research where Telomir-1 markedly reduced intracellular Fe²⁺ levels in human cell systems, with stronger cell-penetrating, iron-lowering activity than the chelator Deferoxamine at the same concentrations. Telomir-1 has also been shown to reduce abnormal DNA methylation in tumor-suppressor genes such as STAT1, CDKN2A, MASPIN, RASSF1A, CASP8, and GSTP1, and to inhibit key lysine histone demethylase (KDM2, KDM5, KDM6) enzyme families. Together, these iron-modulating and epigenetic effects support Telomir’s broader oncology research program, which already includes models of triple-negative breast, pancreatic, and aggressive prostate cancers.
Telomir Pharmaceuticals filed an 8-K reporting new preclinical results for Telomir-1. In human keratinocyte (HaCaT) cells, Telomir-1 produced a strong, dose- and time-dependent reduction of intracellular ferrous iron (Fe²⁺), with greater effect than the FDA‑approved iron chelator Deferoxamine (DFO) under equivalent conditions.
The study used FerroOrange live-cell imaging and observed lower Fe²⁺ signal at three, six, and sixteen hours, indicating cell penetration and iron‑modulating activity at low concentrations. The company also noted a zinc‑formulated version, Telomir‑Zn, designed to exchange metal ions by binding excess reactive metals such as iron and copper while contributing zinc, a cofactor for enzymes tied to antioxidant defense and DNA stability. The findings support ongoing research into metal‑ion balance, oxidative stress, and epigenetic regulation in aging and degenerative disease.
Telomir Pharmaceuticals (NASDAQ: TELO) filed its Q3 2025 10‑Q, reporting ongoing preclinical development and continued losses. Net loss was $1.1 million for the quarter and $8.4 million year‑to‑date, with no revenue. Operating costs in Q3 were $1.15 million, driven by $0.76 million in R&D and $0.39 million in G&A.
Cash rose to $7.33 million as of September 30, 2025, supported by financings: $5.55 million in ATM proceeds during the nine months and a $3.0 million related‑party equity investment at a premium. Subsequent to quarter end, the company raised an additional $1.00 million via ATM block sales. The company disclosed substantial doubt about its ability to continue as a going concern despite indicating current cash is expected to fund operations through the third quarter of 2026.
Shares outstanding were 33,830,971 at September 30, 2025 and 34,380,971 as of November 7, 2025. Telomir executed a binding LOI on October 17, 2025 to acquire TELI Pharmaceuticals, aiming to consolidate worldwide rights to Telomir‑1, with up to $5 million in potential shareholder contributions tied to milestones, subject to approvals.
Telomir Pharmaceuticals (TELO) announced new preclinical data on Telomir-1 in a mouse model of aggressive prostate cancer, focusing on DNA methylation changes in two defense genes, CASP8 (apoptosis) and GSTP1 (glutathione-based detoxification).
On Day 21, Telomir-1 was associated with reduced DNA methylation of both CASP8 and GSTP1 versus vehicle and chemotherapy, suggesting potential re-activation of apoptosis and detoxification-related gene functions. The combination of Telomir-1 and chemotherapy showed lower methylation than chemotherapy alone in this model. Rapamycin showed an initial reduction at Day 10 that partially rebounded by Day 21, while Telomir-1 continued a progressive, more sustained decrease. The company believes DNA-methylation control may be an important area of ongoing evaluation for Telomir-1 in oncology research.